(Q30362729)

11 September 2017

Therapeutic management of diabetic kidney disease. (English)

1 reference

11 September 2017

Daisuke Koya

1

1 reference

11 September 2017

Shin-Ichi Araki

series ordinal

2

1 reference

11 September 2017

Masakazu Haneda

series ordinal

3

1 reference

11 September 2017

language of work or name

1 reference

1 August 2011

1 reference

Journal of Diabetes Investigation

11 September 2017

1 reference

11 September 2017

2

1 reference

11 September 2017

4

1 reference

11 September 2017

248-254

1 reference

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Standards of medical care in diabetes--2011.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Influence of glycemic control on the development of diabetic cardiovascular and kidney disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

The RAAS in the pathogenesis and treatment of diabetic nephropathy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Direct renin inhibition and the kidney

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Global estimates of the prevalence of diabetes for 2010 and 2030

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Residual microvascular risk in diabetes: unmet needs and future directions

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

The Diabetes Control and Complications Trial: the gift that keeps giving

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Lowering blood pressure reduces renal events in type 2 diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Glucose control and vascular complications in veterans with type 2 diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

10-year follow-up of intensive glucose control in type 2 diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Effects of intensive glucose lowering in type 2 diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Telmisartan, ramipril, or both in patients at high risk for vascular events

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10).

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Microalbuminuria as a target to improve cardiovascular and renal outcomes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Antihypertensive agents for primary prevention of diabetic nephropathy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Diabetic nephropathy: diagnosis, prevention, and treatment

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Preventing microalbuminuria in type 2 diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Longitudinal studies on the rate of decline in renal function with age.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

20 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Veterans Affairs diabetes trial--corrections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Effect of telmisartan on renal outcomes: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Regression of microalbuminuria in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00112.X

Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes --- United States and Puerto Rico, 1996-2007.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

An overview of regular dialysis treatment in Japan (as of 31 December 2007).

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4014961

Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group

26 November 2018

1 reference

12 December 2020

Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes

1 reference

12 December 2020

Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes

1 reference

12 December 2020

The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

10.1111/J.2040-1124.2011.00112.X

Identifiers

DOI

1 reference

11 September 2017

1 reference

11 September 2017

1 reference